CENTENNIAL, Colo., July 6, 2016 /PRNewswire-USNewswire/ -- AlloSource, one of the nation's largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, today announced that Dr. Nicole Ehrhart, Professor of Surgical Oncology at the Colorado State University (CSU) Flint Animal Cancer Center, presented preclinical data on adipose-derived mesenchymal stem cells at the State of Spine Surgery 13th Annual Symposium and will present at the Korean American Spine Society meeting on July 9, 2016.
Dr. Ehrhart's preclinical study, entitled Adipose-Derived Mesenchymal Stromal Cells Seeded on Demineralized Bone Matrix Persist and Differentiate When Implanted in a Critical-Sized Rat Femur Defect, used similar technology to AlloSource's AlloStem® Cellular Bone Allograft proprietary, patented process. The preclinical study results showed bone formation within a critical-sized defect in all study subjects. Stem cells were detected for up to 84 days in areas of new formation and differentiated within the bony repair tissue.
"Research is an important part of allograft development and the cellular validation from this study tells a story about AlloStem and its ability to help heal patients," said AlloSource's Vice President of Strategy, Development and Growth, Peter Stevens, PhD. "We look forward to our continued work with Dr. Ehrhart and CSU to maximize the gift of tissue donation."
AlloStem is partially demineralized allograft bone combined with adipose-derived mesenchymal stem cells. Suitable for general bone grafting applications, AlloStem is similar to autograft bone because it provides the three key properties necessary for bone formation: osteoconduction, osteoinduction and osteogenesis.
"AlloSource has consistently led the field in the quality and quantity of preclinical research behind their cell-based products," said Dr. Ehrhart. "This work is another example of how the company has pursued high quality, hypothesis-driven science to more thoroughly understand how AlloStem promotes bone formation in challenging bone healing environments."
Dr. Ehrhart's study has also been accepted for publication in Journal of Biomaterials and Tissue Engineering.
AlloSource is one of the largest nonprofit cellular and tissue networks in the country, offering more than 200 types of precise cartilage, cellular, bone, skin and soft-tissue allografts to advance patient healing. For more than 20 years, AlloSource's products have bridged the proven science of allografts with the advanced technology of cells, offering life-saving and life-enhancing possibilities in spine, sports medicine, foot and ankle, orthopedic, reconstructive, trauma and wound care procedures. As the world's largest processor of cellular bone allografts, fresh cartilage tissue for joint repair and skin allografts to help heal severe burns, AlloSource delivers unparalleled expertise and service to its growing network of surgeons, partners, and the country's most reputable organ procurement organizations. The company is accredited by the American Association of Tissue Banks and is headquartered in Centennial, CO. For more information, please visit allosource.org or our educational website, allograftpossibilities.org.
720. 382. 2766
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/preclinical-study-validates-science-behind-allosources-allostem-cellular-bone-allograft-300294773.html